In NIH trial, selumetinib shrinks tumors, provides clinical benefit for children with NF1
National Institutes of Health (NIH) sent this bulletin at 03/18/2020 05:30 PM EDTHaving trouble viewing this email? View it as a Web page.
You are receiving this message because you are subscribed to News Releases for National Institutes of Health (NIH).
03/18/2020 05:00 PM EDT
Children experienced reduced pain, improved function, and better overall quality of life.